hemophilia bs การใช้

• Subsequent genetic studies have determined that Alexei had hemophilia B.
• Testing for factor IX may also be performed if hemophilia B is suspected.
• It is used to treat hemophilia B, which affects about 2, 800 people.
• As the tsesarevich suffered from an incurable disease, hemophilia B, his life expectations were short.
• Factor IX was discovered in 1952 in a young patient with hemophilia B named Stephen Christmas ( 1947 1993 ).
• Benefix is designed to treat patients with Hemophilia B, who suffer from a lack of factor IX, which helps the blood coagulate.
• Researchers believe hemophilia B is suitable for gene therapy because the factor IX gene is small and a healthy copy can be easily substituted.
• The product is designed to treat patients with Hemophilia B, who suffer from a lack of factor IX, which helps the blood coagulate.
• For instance, deficiency of Factor VIII causes classic Hemophilia A while deficiencies of Factor IX cause " Christmas disease " ( hemophilia B ).
• DNA testing on the remains of the royal family proved in 2009 that Alexei suffered from hemophilia B, a rarer form of the disease.
• DNA testing on the remains of the royal family proved conclusively in 2009 that Alexei suffered from Hemophilia B, a rarer form of the disease.
• The blood-clotting research involves hemophilia B, which afflicts about 5, 000 Americans, or 20 percent of all hemophiliacs in the United States.
• Avigen's current project doesn't affect Bayer's Berkeley plant, because the gene therapy is aimed at the less common hemophilia B.
• Although the potential market for hemophilia B remedies is relatively small, just $ 350 million a year, Bayer is buying into the cutting edge of biotechnology.
• If all goes according to plan, that waiting will certainly be worthwhile for the roughly 8, 000 people in the developed world who suffer from hemophilia B.
• Only about one-fifth of all hemophiliacs suffer from Hemophilia B, which means about 3, 000 people in the U . S ., the company said.
• The blood-clotting treatment, known as Benefix, for hemophilia B, was recommended for approval last week by an advisory panel to the Food and Drug Administration.
• In the hemophilia B trial, the vector carries the correct version of the human gene for Factor IX, one of the many proteins involved in making blood clot.
• Researchers at Children's Hospital of Philadelphia and Stanford University cautioned that their success in treating hemophilia B, a relatively rare form of the illness, was preliminary.
• Lusher and colleagues reported on the peculiar side effect profile ( i . e ., anaphylaxis, nephrotic syndrome ) of recombinant factor IX in patients with hemophilia B.